Proteomics for biodefense applications: Progress and opportunities

Expert Review of Proteomics

Volumn 2, Issue 2, 2005, Pages 203-213

  Drake, Richard R ^a   Deng, Yuping ^a   Schwegler, E Ellen ^a   Gravenstein, Stefan ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

2D SDS PAGE; Biodefense; Biomarkers; ICAT; Immunoproteomics; MALDI; SELDI

Indexed keywords

INFLUENZA VACCINE;

BIOLOGICAL WARFARE; BIOMEDICINE; HUMAN; IMMUNE RESPONSE; INFECTION; INFLUENZA VIRUS; MASS SPECTROMETRY; PROTEIN TARGETING; PROTEOMICS; REVIEW;

ADULT; ANIMALS; BIOTERRORISM; COMMUNICABLE DISEASES, EMERGING; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

INFLUENZA VIRUS;

EID: 17244377812     PISSN: 14789450     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789450.2.2.203     Document Type: Review

References (82)

1. English RD, Warscheid B, Fenselau C, Cotter RJ. Bacillus spore identification via proteolytic peptide mapping with a miniaturized MALDI TOF mass spectrometer. Anal. Chem. 75(24), 6886-6893 (2003).
2. Cordwell SJ, Nouwens AS, Walsh BJ. Comparative proteomics of bacterial pathogens. Proteomics 1(4), 461-472 (2001).
3. Klade CS. Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4(3), 216-223 (2002).
4. Lai EM, Phadke ND, Kachman MT et al. Proteomic analysis of the spore coats of Bacillus subtilis and Bacillus anthracis. J. Bacteriol. 185(4), 1443-1454 (2003). Illustrates the ability of proteomics to generate comprehensive and comparative subproteome information.
5. Elhanany E, Barak R, Fisher M, Kobiler D, Altboum Z. Detection of specific Bacillus anthracis spore biomarkers by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 15(22), 2110-2116 (2001).
6. Thulasiraman V, McCutchen-Maloney SL, Motin VL, Garcia E. Detection and identification of virulence factors in Yersinia pestis using SELDI ProteinChip system. Bio Techniques 30(2), 428-432 (2001).
7. Winkler MA, Uher J, Cepa S. Direct analysis and identification of Helicobacter and Campylobacter species by MALDI-TOF mass spectrometry. Anal. Chem. 71(16), 3416-3419 (1999).
8. Gygi SP, Rist B, Griffin TJ, Eng J, Aebersold R. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J. Proteome Res. 1(1), 47-54 (2002).
9. Hardwidge PR, Rodriguez-Escudero I, Goode D et al. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli. J. Biol. Chem. 279(19), 20127-20136 (2004). Application of isotope-coded affinity tag techniques to proteome analysis of bacterial pathogens.
10. Coldham NG, Woodward MJ. Characterization of the Salmonella typhimurium proteome by semi-automated two dimensional HPLC-mass spectrometry: detection of proteins implicated in multiple antibiotic resistance. J. Proteome Res. 3(3), 595-603 (2004).
11. Liu H, Bergman NH, Thomason B et al. Formation and composition of the Bacillus anthracis endospore. J. Bacteriol. 186(1), 164-178 (2004).
12. Bogdanov B, Smith RD. Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom Rev. 24(2), 168-200 (2004).
13. Peterson J, Umayam LA, Dickinson TM, Hickey EK, White O. The comprehensive microbial resource. Nucleic Acids Res. 29(1), 123-125 (2001).
14. Pleissner KP, Eifert T, Buettner S et al. Web-accessible proteome databases for microbial research. Proteomics 4(5), 1305-1313 (2004).
15. Moore A. Bugging the bugs. Genomics and proteomics may provide new ways of making the lives of bacteria more miserable. EMBO Rep. 4(4), 341-344 (2003). A good resource for database link information.
16. Hoogland C, Mostaguir K, Sanchez JC, Hochstrasser DF, Appel RD. SWISS-2DPAGE, ten years later. Proteomics 4(8), 2352-2356 (2004).
17. Friedman DB, Hill S, Keller JW et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4(3), 793-811 (2004).
18. Yan JX, Devenish AT, Wait R, Stone T, Lewis S, Fowler S. Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics 2(12), 1682-1698 (2002).
19. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDI-TOF MS for diagnostic proteomics. Anal. Chem. 75(7), 148A-155A (2003).
20. Wright GL Jr. SELDI ProteinChip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn. 2(6), 549-563 (2002).
21. Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J. Biomol. Tech. 15(3), 167-175 (2004).
22. Pusch W, Flocco MT, Leung SM, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics 4(4), 463-476 (2003).
23. Warscheid B, Fenselau C. Characterization of Bacillus spore species and their mixtures using postsource decay with a curved-field reflection. Anal. Chem. 75(20), 5618-5627 (2003).
24. Warscheid B, Fenselau C. A targeted proteomics approach to the rapid identification of bacterial cell mixtures by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 4(10), 2877-2892 (2004). Highlights the cutting edge application of matrix-assisted laser desorption/ionization (MALDI)-type analyses to develop rapid assays capable of distinguishing mixtures of pathogens.
25. Warscheid B, Jackson K, Sutton C, Fenselau C. MALDI analysis of Bacilli in spore mixtures by applying a quadrupole ion trap time-of-flight tandem mass spectrometer. Anal. Chem. 75(20), 5608-5617 (2003). Highlights the cutting edge application of MALDI-type analyses to develop rapid assays capable of distinguishing mixtures of pathogens.
26. Kim HS, Sherman D, Johnson F, Aronson AI. Characterization of a major Bacillus anthracis spore coat protein and its role in spore inactivation. J. Bacteriol. 186(8), 2413-2417 (2004).
27. van Ert MN, Hofstadler SA, Jiang Y et al. Mass spectrometry provides accurate characterization of two genetic marker types in Bacillus anthracis. Bio Techniques 37(4), 642-644, 646, 648 passim (2004).
28. Keim P, Price LB, Klevytska AM et al. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J. Bacteriol. 182(10), 2928-2936 (2000).
29. Henriques AO, Moran CP Jr. Structure and assembly of the bacterial endospore coat. Methods 20(1), 95-110 (2000).
30. Todd SJ, Moir AJ, Johnson MJ, Moir A. Genes of Bacillus cereus and Bacillus anthracis encoding proteins of the exosporium. J. Bacteriol. 185(11), 3373-3378 (2003).
31. Steichen C, Chen P, Kearney JF, Turnbough CL Jr. Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J. Bacteriol. 185(6), 1903-1910 (2003).
32. Ren Y, He QY, Fan J et al. The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome. Proteomics 4(11), 3477-3484 (2004).
33. Yip TT, Chan JW, Cho WC et al. Protein Chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin. Chem. 51(1), 47-55 (2005). Illustrates how serum proteomics can be applied to viral disease outbreaks such as severe acute respiratory syndrome (SARS).
34. Poon TC, Chan KC, Ng PC et al. Serial analysis of plasma proteomic signatures in pediatric patients with severe acute respiratory syndrome and correlation with viral load. Clin. Chem. 50(8), 1452-1455 (2004). Illustrates how serum proteomics can be applied to viral disease outbreaks such as SARS.
35. Kang X, Xu Y, Wu X et al. Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin. Chem. 51(1), 56-64 (2005). Illustrates how serum proteomics can be applied to viral disease outbreaks such as SARS.
36. Chen JH, Chang YW, Yao CW et al. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc. Natl Acad. Sci. USA 101(49), 17039-17044 (2004).
37. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3(4), 367-378 (2004).
38. De Groot AS. Immunome-derived vaccines. Expert Opin. Biol. Ther. 4(6), 767-772 (2004).
39. Jungblut PR. Proteome analysis of bacterial pathogens. Microbes Infect. 3(10), 831-840 (2001).
40. Krah A, Jungblut PR. Immunoproteomics. Methods Mol. Med. 9419-9432 (2004).
41. Havlasova J, Hernychova L, Halada P et al. Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics 2(7), 857-867 (2002). Illustration of applying immunoproteomic methods to vaccine development.
42. Ariel N, Zvi A, Makarova KS et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect. Immun. 71(8), 4563-4579 (2003). Illustration of applying immunoproteomic methods to vaccine development.
43. Chidaru T, Ariel N, Zvi A et al. Identification of chromosomally encoded membranal polypeptides of Bacillus anthracis by a proteomic analysis: prevalence of proteins containing S-layer homology domains. Proteomics 4(3), 677-691 (2004).
44. Peng X, Ye X, Wang S. Identification of novel immunogenic proteins of Shigella flexneri 2a by proteomic methodologies. Vaccine 22(21-22), 2750-2756 (2004).
45. Covert BA, Spencer JS, Orme IM, Belisle JT. The application of proteomics in defining the T-cell antigens of Mycobacterium tuberculosis. Proteomics 1(4), 574-586 (2001).
46. Shoshan SH, Admon A. MHC-bound antigens and proteomics for novel target discovery. Pharmacogenomics 5(7), 845-859 (2004).
47. Purcell AW, Gorman JJ. Immunoproteomics: mass spectrometry-based methods to study the targets of the immune response. Mol. Cell. Proteomics 3(3), 193-208 (2004).
48. Krug RM. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res. 57(1-2), 147-150 (2003).
49. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med. 123(7), 518-527 (1995).
50. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
51. Nichol KL, Margolis KL, Wuorenma J, von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331(12), 778-784 (1994).
52. Fedson DS. Influenza prevention and control. Past practices and future prospects. Am. J. Med. 82(6A), 42-47 (1987).
53. Gentile D, Doyle W, Whiteside T, Fireman P, Hayden FG, Skoner D. Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection. Clin. Diagn. Lab. Immunol. 5(5), 604-608 (1998).
54. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J. Clin. Invest. 101(3), 643-649 (1998).
55. Webster RG. Immunity to influenza in the elderly. Vaccine 18(16), 1686-1689 (2000).
56. Falsey AR, Cunningham CK, Barker WH et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172(2), 389-394 (1995).
57. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired Type 1 T-cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 172(6), 3437-3446 (2004).
58. Beamer LJ. Structure of human BPI (bactericidal/permeability-increasing protein) and implications for related proteins. Biochem. Soc. Trans. 31(Pt 4), 791-794 (2003).
59. Ghafouri B, Kihlstrom E, Stahlbom B, Tagesson C, Lindahl M. PLUNC (palate, lung and nasal epithelial clone) proteins in human nasal lavage fluid. Biochem. Soc. Trans. 31(Pt 4), 810-814 (2003).
60. Semmes OJ, Adam B, Banez LL et al. Evaluation of SELDI-TOF-MS serum protein profiling for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Cancer Res. (2005) (In press).
61. Whiting GC, Rijpkema S, Adams T, Corbel MJ. Characterization of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 22(31-32), 4245-4251 (2004).
62. Eschenbrenner M, Wagner MA, Horn TA et al. Comparative proteome analysis of Brucella melitensis vaccine strain Rev 1 and a virulent strain, 16M. J. Bacteriol. 184(18), 4962-4970 (2002).
63. Riedel K, Arevalo-Ferro C, Reil G, Gorg A, Lottspeich F, Eberl L. Analysis of the quorum-sensing regulon of the opportunistic pathogen Burkholderia cepacia H111 by proteomics. Electrophoresis 24(4), 740-750 (2003).
64. Dykes GA, Sampathkumar B, Korber DR. Planktonic or biofilm growth affects survival, hydrophobicity and protein expression patterns of a pathogenic Campylobacter jejuni strain. Int. J. Food Microbiol. 89(1), 1-10 (2003).
65. Skultety L, Hernychova L, Toman R, Kroca M, Stulik J, Macela A. Initial peptide mass fingerprinting analysis of proteins obtained by lysis of Coxiella burnetii cells. Acta Virol. 48(1), 29-33 (2004).
66. Zheng S, Schneider KA, Barder TJ, Lubman DM. Two-dimensional liquid chromatography protein expression mapping for differential proteomic analysis of normal and O157:H7 Escherichia coli. Bio Techniques 35(6), 1202-1212 (2003).
67. Hubalek M, Hernychova L, Brychta M, Lenco J, Zechovska J, Stulik J. Comparative proteome analysis of cellular proteins extracted from highly virulent Francisella tularensis ssp. tularensis and less virulent F. tularensis ssp. holarctica and F. tularensis ssp. mediaasiatica. Proteomics 4(10), 3048-3060 (2004).
68. Hernychova L, Stulik J, Halada P et al. Construction of a Francisella tularensis two-dimensional electrophoresis protein database. Proteomics 1(4), 508-515 (2001).
69. Folio P, Chavant P, Chafsey I, Belkorchia A, Chambon C, Hebraud M. Two-dimensional electrophoresis database of Listeria monocytogenes EGDe proteome and proteomic analysis of mid-log and stationary growth phase cells. Proteomics 4(10), 3187-3201 (2004).
70. Schaumburg J, Diekmann O, Hagendorff P et al. The cell wall subproteome of Listeria monocytogenes. Proteomics 4(10), 2991-3006 (2004).
71. Starck J, Kallenius G, Marklund BI, Andersson DI, Akerlund T. Comparative proteome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions. Microbiology 150(Pt 11), 3821-3829 (2004).
72. Schmidt F, Donahoe S, Hagens K et al. Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope-coded affinity tag technology. Mol. Cell. Proteomics 3(1), 24-42 (2004).
73. Chao CC, Chelius D, Zhang T, Daggle L, Ching WM. Proteome analysis of Madrid E strain of Rickettsia prowazekii. Proteomics 4(5), 1280-1292 (2004).
74. Yoon H, Lim S, Heu S, Choi S, Ryu S. Proteome analysis of Salmonella enterica serovar Typhimurium fis mutant. FEMS Microbiol. Lett. 226(2), 391-396 (2003).
75. Deiwick J, Rappl C, Stender S, Jungblut PR, Hensel M. Proteomic approaches to Salmonella pathogenicity island 2 encoded proteins and the SsrAB regulon. Proteomics 2(6), 792-799 (2002).
76. Zeng R, Ruan HQ, Jiang XS et al. Proteomic analysis of SARS associated coronavirus using two-dimensional liquid chromatography mass spectrometry and one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by mass spectroemetric analysis. J. Proteome Res. 3(3), 549-555 (2004).
77. Cohen AM, Rumpel K, Coombs GH, Wastling JM. Characterization of global protein expression by two-dimensional electrophoresis and mass spectrometry: proteomics of Toxoplasma gondii. Int. J. Parasitol. 32(1), 39-51 (2002).
78. Kan B, Habibi H, Schmid M et al. Proteome comparison of Vibrio cholerae cultured in aerobic and anaerobic conditions. Proteomics 4(10), 3061-3067 (2004).
79. Coelho A, de Oliveira Santos E, Faria ML et al. A proteome reference map for Vibrio cholerae El Tor. Proteomics 4(5), 1491-1504 (2004).
80. Chromy BA, Perkins J, Heidbrink JL et al. Proteomic characterization of host response to Yersinia festis and near neighbors. Biochem. Biophys. Res. Commun. 320(2), 474-479 (2004).
81. Schwegler EE, Cazares LH, Steel LF et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41(3), 634-642 (2005).
82. Grandi G, Zagursky R. The impact of genomics in vaccine discovery: achievements and lessons. Expert Rev. Vaccines 3(6), 621-623 (2004).